For this reason, their activity is enhanced by major therapeutics, which include PD-1 antibodies that function as a blockade for inhibitory T cell receptors, as well as genetically engineered T cells, which express chimeric antigen receptors (CARs) specific towards the tumor [38,39]. The gene discussed is PDCD1; the disease is neoplasm.